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Abstract  
Background: Allergic diseases have seen a rise worldwide in the last two decades, 
with children suffering the highest burden of the condition. The ω-3 Long-Chain 
Poly-Unsaturated fatty Acid (LCPUFA) poses anti-inflammatory properties that could 
lead to a reduction in inflammatory mediators in allergies.  
Objective: A systematic review and meta-analysis of the most recent follow-ups of 
randomised controlled trials (RCTs) was conducted to assess the effectiveness of ω-3 
LCPUFA supplementation started during pregnancy on allergic outcomes in 
offspring.  
Methods: RCTs with a minimum of 1-month follow-up post gestation were eligible 
for inclusion. The CENTRAL, MEDLINE, SCOPUS, WHO's International Clinical 
Trials Register, E-theses and Web of Science databases were searched. Study quality 
was evaluated using the Cochrane Collaboration's risk of bias tool.  
Results: Ten RCTs (3,637 children), from nine unique trials examined the 
effectiveness of ω-3 LCPUFA supplementation started during pregnancy on the 
development of allergic outcomes in offspring. There were heterogeneities between 
the trials in terms of their sample, type and duration of intervention and follow-up. 
Pooled estimates showed a significant reduction in childhood “sensitisation to egg” 
(Relative Risk (RR)=0.54, 95% Confidence Interval (CI)=0.32-0.90) and 
“sensitisation to peanut” (RR=0.62, 95% CI=0.40-0.96). No statistical differences 
were found for other allergic outcomes e.g. any allergies, eczema, asthma/wheeze.  
Conclusion: These results suggest intake of ω-3 LCPUFA started during pregnancy 
can reduce the risk of sensitisation to egg and peanut; however the evidence is limited 
due to the small number of studies contributed to meta-analyses. The current evidence 
on the association between supplementation with ω-3 LCPUFA started during 
pregnancy and allergic outcomes is weak due to the risk of bias and heterogeneities 
between studies.  
Key words: Systematic Review, Meta-analysis, omega-3 Fatty acids, Fish oil, n-3 
LCPUFA, Allergies, Childhood allergies, Asthma, Wheeze, Wheezing, 
Asthma/wheeze, Sensitisation, Food allergy, Eczema 
Introduction 
In the last two decades allergic diseases have seen a rise worldwide with children 
suffering the highest burden of the condition
(1)
. Food allergies, eczema and asthma are
the most common allergic disorders in children
(1-2)
. The increasing burden of allergic
conditions is an important public health concern and understanding how to prevent 
the development of allergic diseases is a vital area of research. 
The first 1,000 days of life is key to good health for a lifetime as the developmental 
model of health and disease states exposures and incidents during this critical period 
could initiate the susceptibility of many chronic diseases, including allergies
(3)
. In this
context, the role of environmental factors such as diet and lifestyle-related behaviours 
are key for primary/early prevention of chronic diseases
(4-5)
. Factors such as maternal
diet could directly affect an infant’s health and immune system(6-7). On this basis,
interventions that aim to improve nutritional adequacy in pregnant women could, in 
theory, reduce the incidence of chronic diseases including allergy. 
The intake of LCPUFAs, particularly the ω-3/ω-6 ratio, has been proposed as a risk 
factor for childhood allergies. Over recent decades, Western diet has shifted towards 
higher intake of ω-6 by increased consumption of vegetable oils and a corresponding 
decrease in intake of foods rich in ω-3 PUFAs e.g. seafood and oily fish(8-9). The
LCPUFAs family, mostly known by ω-3 and ω-6 products, is involved in immune-
regulation and inflammatory pathways in foetuses
(10); with ω-3 fatty acids having
anti-inflammatory, and ω-6 fatty acids pro-inflammatory effects(11). Higher
concentrations of ω-6 LCPUFAs promote the production of inflammatory mediators 
such as prostaglandins (PGE2, F2α) and leukotriene (LTB4), which compete with the 
synthesis of ω-3 in cellular phospholipids membranes(11). Subsequently, a diet rich in
sources of ω-3 LCPUFAs could lead to a reduction in inflammatory mediators and 
also alter the balance of TH1 to TH2
(12-13)
, a recognised hallmark of allergic diseases.
Furthermore, observational studies summarised in a narrative systematic review
(14)
have shown an association between lower levels of oily fish intake during pregnancy 
and the development of allergies in children. Collectively, these data suggest that ω-3 
fatty acid supplementation during pregnancy may be a strategy to reduce childhood 
allergies. 
The effect of exposure to an increased supply of ω-3 LCFUFA (or in combination 
with ω-6) in utero and the risk of developing allergic disorders has been studied in 
various trials; however these have produced inconsistent results. This systematic 
review and meta-analysis aimed to assess the effectiveness of these interventions, 
including the longest available follow-ups reported. This will provide an update to the 
earlier systematic reviews on this topic
(15-17)
 to include recently published trials. It
would also allow us to assess the effectiveness of ω-3 LCFUFA supplementation 
commencing during pregnancy for prevention of childhood allergies, while the focus 
of earlier systematic reviews on this topic has been on both the prenatal and postnatal 
ω-3 LCPUFA interventions.  
Methods 
Criteria for considering studies for this review 
Types of studies 
Randomised controlled trials (RCT), including cluster randomised controlled trials 
and quasi-randomised controlled trials with a minimum follow-up of one month 
postnatally were included. The review considered studies which documented allergic 
outcome and/or sensitisation data. No language or country restrictions were applied.  
Types of participants 
Pregnant women and their offspring were considered as the target group for this 
systematic review. High-risk populations were not excluded. 
Types of interventions 
Studies that used ω-3 LCPUFA supplementation during pregnancy, irrespective of 
dose, formulation or mode of delivery and composition e.g. oil, tablet were included. 
Trials were also included if the intervention(s) had been continued after pregnancy 
through breast-feeding and/or supplements to the infant.  
Types of outcomes measures 
Trials were included if they had reported allergic outcomes and/or sensitisation in the 
offspring, either as a primary or secondary endpoint. Allergic outcomes were defined 
as: any allergies, asthma, wheeze, rhinitis, eczema, food allergy, positive skin prick 
test (to any and/or single allergens) or elevated specific IgE. Only outcomes which 
had utilised a validated method were included (as opposed to, for example, parental 
report). Data from the latest follow-up of allergic outcomes by the included trials (and 
cumulative prevalence where possible) were also considered.  
Search strategy for identification of studies 
A comprehensive search strategy, including all the relevant synonyms for the main 
concepts, was developed. Trials were identified through systematic searches within 
three main electronic databases, as advised by the Cochrane collaboration
(18)
:
a. Cochrane Library (current issue) including:
 Cochrane Database of Systematic Reviews (CDSR)
 CENTRAL (trials)
 DARE
b. MEDLINE (EBSCOhost)
c. SCOPUS
When searching MEDLINE, the subject-specific terms were combined with the 
Cochrane Highly Sensitive Search Strategy for identifying randomised trials in 
MEDLINE: sensitivity-maximising version
(18)
. We adapted the preliminary search
strategy for MEDLINE (EBSCOhost) for use in the other databases when relevant. 
Searches of databases were carried out between November 2017 to January 2018.  
The clinical trials registry and WHO platform were searched for ongoing and recently 
completed trials. Conference proceedings were identified through the ISI Web of 
Science and the British Library E-Theses Online Service was searched. No language 
or publication status restrictions were imposed. References of included studies were 
crosschecked for additional studies.   
Data collection  
Selection of studies 
Two reviewers (MV, HM) screened all the search results against the eligibility criteria 
and all those which were clearly irrelevant were excluded from further consideration. 
Thereafter, a tailored eligibility form was used to appraise the retrieved studies, 
abstract and full text for relevance against the full inclusion criteria. Where there was 
uncertainty about inclusion of a particular study, other members of the review team 
were consulted and a consensus was reached about the study eligibility. All the 
included studies were discussed and approved by the review team.  
Data extraction and management 
Data were extracted by two reviewers (MV, HM) using a tailored data extraction form 
in EPPI Reviewer. Detailed information on study characteristics were recorded. 
Throughout the data extraction process, any disagreements about the interventions 
and outcomes were discussed and resolved within the review team. There was no 
blinding of the authors’ name, institutions, journals or the outcomes of the trials 
during the process.  
Assessment of risk of bias in included studies 
The risk of bias tool described in the Cochrane Handbook for Systematic Reviews for 
Interventions was used to appraise the studies
(19)
.
Data synthesis  
Calculation of treatment effects 
Dichotomous data were analysed as risk ratios or relative risk (RR) with 95% CI, 
entered as events and the number of participants, and continuous data as mean 
difference or standardised mean difference, with 95% CI. In trials with more than one 
intervention arm, multiple pairwise comparisons of intervention groups versus 
comparator were avoided. Therefore, data from different intervention arms were 
pooled for an overall comparison with the control or placebo arm. The weight 
assigned to the control group was considered as the total number of participants in the 
comparator group versus the total number of participants in the combined intervention 
arms
(20)
.
All the relevant reported information for the number of missing participants was 
extracted and if undocumented, this was incorporated into the assessment of risk of 
bias, incomplete outcome data. No imputed techniques were used for missing data.  
Pooling of treatment effects  
Assessment of heterogeneity 
We used visual inspection of forest plots and also, the Chi
2
 test to measure statistical
heterogeneity between effect sizes of included studies. I
2 
statistics were used to
quantify the amount of possible variability in effect estimates that is due to 
inconsistency rather than chance (I
2
<25% low heterogeneity, I
250 moderate
heterogeneity, I
2 ≥75 high heterogeneity). All meta-analyses were undertaken using
a random effect model and reported where heterogeneity was reported as ≤75%(18).
Assessment of reporting biases 
Every effort was made to identify unpublished studies through searching abstracts and 
ongoing trials databases. Small study effects was not assessed since the number of 
studies included in meta-analyses were ≤10. 
We used Eppi Reviewer version 4.4.3.0. for conducting meta-analyses. We reported 
relative risk to describe the study effect. Due to the small number of studies and also, 
large inconsistencies between studies, the reported allergic outcomes were included in 
meta-analyses irrespective of IgE status. 
Subgroup analysis and investigation of heterogeneity  
Where possible, sub-group analyses were performed where there was large 
discrepancies in the duration of follow-up between the included studies e.g. less than 
and above 6 years old.  Additional analyses were also conducted when level of 
maternal EPA+DHA pre-treatment was reported in the trials. 
Sensitivity analysis 
Influence analysis as a type of sensitivity analysis was conducted where trials were 
excluded from the meta-analyses models to examine how deletion of a study affects 
overall results. This was done for trials that used either a different intervention or 
control group. 
Results 
Electronic searches yielded a total of 1,733 results (Figure 1). After removal of 
duplicates and title/abstract screening, the remaining 79 full text papers were assessed 
against the eligibility criteria for this systematic review. Ten publications from nine 
unique RCTs were included in the final analyses, including a total of 3,637 children
(21, 
28, 30, 32, 34, 38, 43, 47, 48, 50)
. In the case of one trial
(29)
, both the reports of an earlier
(28)
 as
well as latest follow-up data
(47)
 were included, since some of the allergic outcomes of
interest for this systematic review were reported only in the earlier published paper of 
this trial i.e. any allergic diseases. The characteristics of the included trials, their 
companion papers and study population are presented in Table 1. Four studies were 
conducted in Australia and Denmark (two each) and the rest in Mexico, Sweden, 
Finland, United Kingdom and United States.  
Study design 
All the included trials were parallel RCTs. Seven trials had two parallel groups while 
two trials had three parallel groups. The trial by Olsen
(30)
 included intervention,
placebo and no oil groups and for the purpose of this review, only the intervention 
and placebo arms were included in meta-analyses. The other trial by Berman
(50)
included two intervention groups of EPA, DHA and placebo.  For this review, the two 
intervention arms were combined and compared versus the control group. In addition, 
the nature of control group in the study by Noakes
(34)
 was different from other trials
i.e. standard diet and therefore, this study was not included in meta-analyses and only
described narratively. 
Participants and sample sizes 
Four trials were conducted on high-risk (atopy) populations
(21, 32, 34, 38)
 and the
remainder
(28, 30, 43, 47, 48, 50)
 were carried out on sample with low-risk allergies. The
sample size of studies at randomisation were also varied, from 98
(21)
 to 1,094
(43)
pregnant women.  
Intervention 
Seven of the included trials used ω-3 LCPUFA (combination of EPA, DHA and/or 
both)
(21, 28, 32, 38, 43, 47, 48, 50)
, one used oily fish
(34)
 and the other used black currant seed
oil (BCSO)
(30)
. Six
(21, 28, 34, 38, 43, 47, 50)
 trials supplemented women only during
pregnancy and in three trials
(30, 32, 48)
, the intervention was continued postnatally
(Table 1). 
Compliance with the intervention was measured by different methods in trials, 
including total number of capsules consumed, women’s self-report of oily fish intake 
using food frequency questionnaire during pregnancy, telephone call reminder(s), as 
well as assessing plasma concentration of LCPUFA either at birth or a few weeks 
after delivery
(21, 28, 32, 34, 38, 47)
.
Reported allergic outcomes and follow-up duration 
Allergic outcomes were diagnosed by a physician or nurse in 6 trials
(21, 30, 32, 34, 38, 48)
and the remainder
(28, 43, 50)
 used validated or semi-validated questionnaires. The
definitions and diagnosis method for each outcome included in meta-analyses are 
presented in Table 2. The duration of follow-up in trials ranged from 6months
(34)
 to 24
years
(47)
.
The most frequently reported allergic outcomes were eczema, asthma, wheeze or 
asthma/wheeze together. Also, while there was a later publication from a study 
published in 2010
(31)
, data were extracted from the 2010 report since the follow-up
paper
(30)
 only reported pre-clinical outcomes. Furthermore, the register-based
outcomes in the study by Hansen 2016 were considered in this review. In addition, 
two trials
(28, 50)
 were primarily conducted to measure other outcomes in pregnant
women and, using secondary analyses, the occurrence of allergic outcomes in the 
offspring were also reported. Olsen and colleagues
(29)
 principally assessed the effect
of LCPUFA on the duration of pregnancy and reported allergic outcomes in the 
offspring in the longer-term follow-ups. The trial conducted by Berman
(50)
 initially
measured the effectiveness of ω-3 LCPUFA for prevention of antenatal and 
postpartum depressive symptoms in pregnant women and reported the occurrence of 
allergic outcomes in their secondary analysis.  
Quality of RCTs 
The methodological quality of the included trials varied as shown in Figure 2. The 
risk of bias judgment is presented in Appendix 1. Only four trials
(30, 34, 38, 43)
 had a low
risk regarding random sequence generation. Most trials had adequate allocation 
concealment
(21, 28, 38, 43, 47)
, blinding of both participants and staff
(21, 30, 32, 43, 47, 48)
, and
outcome assessor
(21, 28, 30, 32, 34, 38, 43, 47)
. Half of the trials were rated as high risk of bias
for the completeness of data since there was a high rate of loss to follow-up. All trials 
were deemed to have a low risk of bias for the reported outcomes
(21, 32, 30, 34, 50)
. With
the exception of one trial rated as unclear for other sources of bias
(48)
, there were no
other potential sources of bias in other trials.  
Pooled effect of interventions 
The definition of the outcomes in each study, as included in meta-analyses, and their 
diagnosis method are presented in Table 2.  
Any allergies as outcome measure 
Three trials
(28, 32, 38)
 reported any allergies in children characterised by different
phenotypes of allergy. Moderate statistical heterogeneity was observed between the 
trials (χ2=5.54, P=0.06, I2=63.9%) and the pooled results did not show an association
between prenatal supplementation with ω-3 LCPUFA and the development of any 
allergies in the offspring (RR=0.74, 95% CI=0.44-1.25) (Forest plot not shown). The 
definitions of any allergies included in meta-analysis are shown in Table 2.  
In the sub-group analysis, the Olsen study
(28)
 with the longest follow-up duration was
excluded. No statistical heterogeneity was found between the included trials (I
2
=0%)
and the results did not significantly change (RR=0.97, 95% CI=0.79-1.19) (Forest 
plot not shown).  
Asthma/wheeze as outcome measure 
Trials reported the outcome differently, as either asthma only, wheezing or 
asthma/wheeze together. When pooling the results, we considered the outcome as 
“asthma and/or wheeze” together in the meta-analysis. Moderate heterogeneity was 
observed between the seven included trials (χ2=10.5; P=0.10; I2=43.1%). Meta-
analysis did not show a preventative effect of prenatal intake of ω-3 LCPUFA on 
childhood asthma/recurrent wheeze (RR=0.87, 95% CI=0.70-1.07) (Figure 3).  
In the sub-group analysis, the study by Hansen
(47)
 with the longest follow-up duration
was excluded. Low heterogeneity was found between the studies (I
2
=21.9%) and the
results did not significantly change (RR=0.93, 95% CI=0.78- 1.11) (Forest plot not 
shown). Also in the study by Bisgaard
(48)
, prevalence of asthma/wheezing in children
was also reported based on maternal lowest third of EPA+DHA pre-treatment. The 
meta-analysis, including this outcome in the model showed higher heterogeneity 
between trials (I
2
=63.8%) and the results did not significantly change (RR=0.83, 95%
CI=0.64-1.08).  
Eczema as outcome measure 
The outcome was reported in six trials and pooled results showed moderate statistical 
heterogeneity between studies (χ2=11.2; P=0.046, I2=55.5%). The results of meta-
analysis did not show an association between prenatal intake of ω-3 LCPUFA and the 
development of childhood eczema (RR=1.01, 95% CI=0.76-1.34) (Figure 4). 
Sensitivity analysis excluding the study conducted by Linnamaa
(30)
, as the only trial to
use BCSO as the intervention, also showed moderate statistical heterogeneity between 
studies (χ2= 9.08; P= 0.059; I2=56%) with no significant change in the pooled results
(RR=1.1, 95% CI=0.78-1.54) (Forest plot not shown). Two more sensitivity analyses 
were conducted. In the first, the study undertaken by Berman
(50)
 was excluded since it
reported higher rates of eczema in the intervention arms and in the second, both 
Linnamaa
(30)
 and Berman
(50)
 studies were excluded. In both meta-analyses, moderate
heterogeneities were observed between studies and the results did not significantly 
change (RR=0.952, 95% CI=0.767-1.18; RR=1.01, 95% CI=0.786-1.29, respectively) 
(Forest plots not shown).  
Allergic rhinitis as outcome measure 
The outcome was reported in two trials
(38, 47)
 and in the two other trials,
“rhinoconjunctivitis” was reported(32, 50). We pooled the results from trials that only
reported allergic rhinitis where there was a moderate heterogeneity between trials 
(χ2=1.37, P=0.243, I2=27%). The results of meta-analysis did not show an association
between prenatal intake of ω-3 LCPUFA and development of allergic rhinitis in 
children (RR=084, 95% CI=0.65-1.1) (Forest plot not shown). 
Food allergy as outcome measure 
Three trials reported the outcome
(21, 32, 50)
 and in the pooled analysis, low
heterogeneity was found between the studies (χ2=2.32, P=0.31, I2=13.8%). The results
of meta-analysis did not show an association between prenatal intake of ω-3 LCPUFA 
and development of food allergy in children (RR=0.67, 95% CI=0.34-1.35) (Forest 
plot not shown). 
Sensitisation to any allergens as outcome measure: 
Sensitisation to any allergens, measured by Skin Prick Test (SPT), was reported in 
four trials
(21, 32, 38, 48)
 and there was moderate heterogeneity between studies (χ2=6.03,
P=0.11, I
2
=50.3%). The results of meta-analysis did not show an association between
prenatal intake of ω-3 LCPUFA and childhood sensitisation to any allergens 
(RR=0.91, 95% CI=0.66-1.27) (Forest plot not shown).  
Sensitisation to specific individual allergens as outcome measure 
The meta-analyses of sensitisation to individual allergens, measured by SPT showed 
that prenatal intake of ω-3 LCPUFA significantly reduced the risk of “sensitisation to 
egg” (RR=0.54, 95% CI=0.32-0.90) (Figure 5) and “sensitisation to peanut” 
(RR=0.62, 95% CI=0.40-0.96) (Figure 6). No significant associations were found for 
sensitisation to “cows milk” and “cat” in the conducted meta-analyses (Forest plots 
not shown).  
Of note, we conducted a meta-analysis on raised specific immunoglobulin E (sIgE), 
reported in three studies
(32, 47, 48)
 and the results yielded a substantial heterogeneity
(I
2
=77.5%) (Forest plot not shown).
Description of the outcomes reported in Noakes study
(34)
This study used ‘farmed salmon portion’ (as opposed to LCPUFA supplements, as 
utilised in all the other included studies) compared to ‘standard diet’ during 
pregnancy for prevention of allergic disorders in offspring, and was therefore not 
included in any meta-analyses. The results suggest that the use of salmon portions in 
pregnant women in comparison to standard diet did not have an influence for the 
prevention of atopic dermatitis (12 vs. 7, p=0.46) and wheeze (11 vs. 7; p=0.58) in the 
offspring by 6 months age; however, the small sample size limits confidence in these 
findings. 
Discussion 
Ten RCTs were identified, with a total number of 3,637 children that started 
supplementation with ω-3 LCPUFA during pregnancy and followed-up the 
development of allergic diseases during childhood. Trials were heterogeneous in their 
sample, reported outcomes and duration of follow-up. Random sequence generation 
was deemed adequate in four of the included trials. Three trials were also judged to 
have a high risk of bias for their performance bias and five trials had a high attrition 
bias. The findings from this systematic review and meta-analysis did not provide 
evidence that intake of ω-3 LCPUFA starting during pregnancy could protect against 
the subsequent development of a number of childhood allergic diseases i.e. eczema, 
asthma/wheeze, food allergy, sensitisation. However, the pooled results showed that 
prenatal intake of ω-3 LCPUFA starting during pregnancy might have a protective 
effect on developing sensitisation to egg and also peanuts in the offspring, as 
measured by SPT. Furthermore, while no effect was observed for childhood 
asthma/wheezing following ω-3 LCPUFA intake starting during pregnancy, the upper 
bound was very close to 1 and could be considered borderline (RR=0.87, 95% 
CI=0.70-1.07, 7 trials, 2,951 children). Overall, the results from this review need to be 
considered with caution because of the heterogeneity observed between studies and 
also risk of bias.  
Overall completeness and applicability of evidence  
There was no evidence that ω-3 LCPUFA supplementation starting during pregnancy 
is effective for prevention of several allergic manifestations in the offspring. There 
were no statistical heterogeneity between the included trials for the outcome of 
“sensitisation to egg and peanuts, measured by SPT” (I2=0%) and however; the
number of included studies were small; the meta-analyses included 665 and 775 
children respectively. Nevertheless, these are potentially important findings since 
food allergies are common in children
(1)
 and well-documented research indicates that
childhood food allergies, including to egg and peanuts, are a key risk factor for 
developing sensitisation to aero-allergens and allergic respiratory diseases later in 
life
(54-57)
.
The heterogeneity between the trials limit the findings and random effect models were 
used to pool the results. Heterogeneity between the included trials could have resulted 
from differences in the choice of ω-3 LCPUFA and the dose, mode of administration, 
timing and duration of interventions as well as duration of follow-up and small 
sample size in most studies. Overall, a few trials were well-powered and high 
quality
(38, 43, 48)
 and contrasting results on childhood allergic outcomes were reported
across trials. One reason for the inconsistent results between trials could be because of 
the differences in baseline ω-3 LCPUFA levels that were only considered in the 
Bisgaard study
(48)
. Children of mothers with the lowest third level of ω-3 LCPUFA
status (EPA and DHA) gained the most protection from ω-3 LCPUFA intervention. 
Higher doses of ω-3 LCPUFA were also used in the trial by Bisgaard that consisted 
predominantly of EPA versus DHA. It is also worth noting that in this study, a 
subgroup of pregnant women concomitantly took a high dose of 2400 IU of Vitamin 
D3 on a daily basis during the third trimester of pregnancy. The authors reported that 
there was no significant interaction between ω-3 LCPUFA and Vitamin D3 and the 
prevalence of persistent wheeze (p=0.065); however further analysis showed that the 
effects of ω-3 LCPUFA was less evident in children randomised to the Vitamin D3 
group
(48)
. Furthermore, in the study by Berman
(50)
, higher numbers of eczema cases
were reported in both intervention arms, EPA and DHA as opposed to soy oil as the 
control. The authors reasoned that ω-6 LCPUFA as the predominant component in the 
soy oil might have exerted a protective effect on developing eczema in the control 
group. It is important to add that none of the high quality and large trials reported a 
beneficial effect for childhood eczema in their longer-term follow-up
(38, 43, 47, 48)
.
Again heterogeneities in the type and dose of ω-3 LCPUFA plus differences in the 
duration of follow-up could be a plausible explanation for the inconsistent results 
between trials.  
Quality of evidence 
Overall, the trials were at moderate to high risk of bias (Figure 2). Randomisation and 
allocation concealment were deemed as unclear for 50% of included studies in each 
domain. High loss to follow-up was also a major concern where 50% of studies 
showed a high attrition bias which might have largely biased the effect of 
interventions within these trials. In addition, a limited number of trials fulfilled the 
inclusion criteria for this systematic review and consequently, a small number of 
studies contributed in the conducted meta-analyses for most allergic outcomes. Most 
trials also used medical diagnosis of allergy, although a few tested for IgE-mediated 
status of the reported allergic outcomes
(38)
. Furthermore, since the diagnosis of asthma
is difficult at a young age, most trials reported wheeze or asthma/wheeze together and 
consequently; either of these reported outcomes were included in meta-analyses. It is 
acknowledged that phenotype expression of allergic diseases in children varies by 
age, as more eczema and food allergy would be expected in children under 2 years of 
age and more wheeze/asthma at older age. Where possible, sub-group meta-analyses 
were conducted to address the age differences for the reported allergic outcomes. 
Strengths and limitations 
This systematic review only included trials that started intake of ω-3 LCPUFA during 
pregnancy, and thus crucially, allowed the effect of prenatal intake of the 
supplementation for prevention of childhood allergies to be investigated. Following 
an a priori published protocol
(58)
, a comprehensive search strategy allowed for a
complete coverage of all the relevant literature through citation databases, trial 
registries and conference proceedings with no limitation by language or publication 
status. In addition, a range of allergic outcomes were considered and the most up-to-
date results from the trials, reported as the longest available follow-up data, were 
included in the meta-analyses. As a post hoc decision, sub-group analyses were only 
conducted for the duration of follow-up and not for the dose/timing/type of ω-3 
LCPUFA because of the limited number of studies that could contribute in the meta-
analyses. A potential limitation is also that there were a small number of studies that 
met the inclusion criteria for this systematic review. 
Consistency with other reviews 
The two reviews published in 2011
(15, 59)
 included studies that administered ω-3
LCPUFA either prenatally or postnatally with the former
(15)
 being a narrative review.
The latter
(59)
 conducted meta-analysis on selected allergic outcomes and did not
include some trials in their review
(34, 40, 43)
.
The two recent reviews by Gunaratne
(15)
 and Best
(16)
 had different approach, with first
including both prenatal and postnatal administration of ω-3 fatty acids(15) and the
other only on prenatal supplementation, but with small number of trials
(16)
. Both
reviews have conducted their meta-analyses based on IgE status of allergic outcomes, 
including point prevalence of allergies and earlier follow-up data of included trials. 
Also, the trial by Linnamaa
(30)
 that used BCSO was only included in the present
review since the composition of BCSO corresponds to the recommended optimal 
dietary intake ω-3 and ω-3 fatty acids with ω-3/ω-6 ratio from 1.3 to 1.4. Due to the 
differences in focus between these systematic reviews and the current review, the 
ability to make meaningful comparisons between the findings is to some extent 
limited. Both reviews
(15 & 16)
 showed a beneficial effect for atopic eczema for some
age strata; however, these analyses only included the earlier follow-up data from 
included trials.  
The most recent review
(17)
 has also included both prenatal and postnatal ω-3 LCPUFA
interventions and has not identified the latest report of one trial
(43)
 and full paper of
another trial
(50)
. There are also differences between the current systematic review and
Garcia-Larsen in term of the approach for inclusion of trials in the conducted meta-
analyses. For example, we did not include the Noakes
(34)
 trial in the meta-analyses
since it had a different control while this study has been included in meta-analyses by 
Garcia-Larsen. Also, the trial by Linnamaa has been considered as ω-6 fatty acid 
intervention in the review by Garcia-Larsen and additionally, they have included 
different reports of Makrides 2009 trial in the meta-analyses conducted for food 
allergy e.g. Palmer 2012 in “egg sensitisation” and Best 2016 in “Peanut 
sensitisation”. Nevertheless, the results from the current systematic review are 
comparable with the recent review
(18)
 where there was evidence that ω-3 LCPUFA
supplementation has been beneficial for prevention of sensitisation to egg and peanut 
in children. Since the current review included ω-3 LCPUFA trials that were only 
started during pregnancy, it can be concluded that the preventive effect of the 
intervention on sensitisation to egg and peanut in children is related to this very early 
stage in life i.e. pregnancy. We also did not find evidence that ω-3 LCPUFA could 
protect against other allergic outcomes in offspring which is similar to the recent 
review
(17)
.
Authors’ conclusion 
Implications for practice 
The evidence on ω-3 LCPUFA intake starting during pregnancy and prevention of 
allergic outcomes in children is limited, although there appears to be an association 
with reduction of childhood sensitisation to egg and peanuts. There is a need to 
interpret these findings with caution as a result of risk of bias between studies, 
different methods for reporting the outcome measures and variability of the ω-3 
LCPUFA supplementations. Furthermore the included trials differed greatly in the 
dose of ω-3 supplementation, ranging from 0.8 to 2.4g per day and contained various 
percentages of EPA and DHA. The current guidelines advise an intake of 200mg of 
DHA per day in pregnancy
(60)
 and differences in the dose/ratio of DHA in the ω-3
supplementation in trials could have consequently had an impact on the overall 
effectiveness of intervention.  
Implications for research  
Taking the quantity and quality of the available evidence into account, the effect of ω-
3 LCPUFA intake starting during pregnancy for prevention of childhood allergies 
needs to be further investigated in well-designed and executed RCTs.  
The timing of interventions have been varied in the conducted trials and the optimal 
timing of ω-3 LCPUFA intervention is an essential uncertainty that needs to be 
addressed more clearly in further trials. Given the anti-inflammatory properties of ω-3 
LCPUFAs, it could be hypothesised that early introduction of ω-3 LCPUFA during 
pregnancy could promote a beneficial immunomodulatory effect in foetuses as early 
as possible by programming the immune system. Furthermore, future trials could 
consider a differentiation between DHA to EPA ratios in LCPUFA supplementations 
as well as baseline LCPUFA status in their sample. The dose and duration of 
intervention as well as the choice of control should also be addressed in future studies. 
Large multi-centre RCTs with coherent methodology and standardised measures for 
assessing the outcomes could provide stronger inferences for the efficacy of ω-3 
LCPUFA intervention in pregnant women as a preventive approach for childhood 
allergies. In addition, studies should aim to minimise the attrition bias in their 
extended follow-ups. There is also a need for well-designed epidemiological studies 
from under-reported populations, since the current evidence originates dominantly 
from the developed regions. 
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Figure 1: Study flow diagram, following PRISMA criteria 
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Table 1. Characteristics of included trials and study population for fatty acids and prevention of allergic and/or respiratory outcomes in 
offspring 
Companion 
articles*
Country, 
enrolmen
t period 
Participants 
receiving 
intervention 
Age 
at last 
F-U
Sample: 
high 
risk of 
Atopy 
Intake of 
Int. 
From/until 
Duration 
of Int. 
(months) 
No. at 
randomis
ation
**
No. at last 
Follow-
up 
Fatty 
acid 
product 
Placebo Total 
daily 
dose 
Outcomes reported 
Dunstan, 
et al., 
2003a 
(21) 
References 
22-27 
Australia 
1999-
2001 
Prenatally in 
mothers 
1yr Yes 20wks to 
delivery 
4.5-5 98 83 (40 vs. 
43) 
ω-3
PUFA 
Olive oil 1-g,
4 a day
-Asthma
-Recurrent wheeze
-Eczema
-SPT (any+); (egg)
(peanut) (HDM)
(cows milk) (CAT)
-Food Allergy
-Anaphylaxis
-Angioedema
-Chronic cough
-SCORAD >=25
Olsen et 
al., 2008 
(28) 
Reference 
29 
Denmark 
1989-90 
Prenatally in 
mothers 
16yrs No 30wks to 
delivery 
2-2.5 533: 266 
vs. 131 vs. 
136 
528 (263 
vs. 129 vs. 
136) 
Fish oil  Olive 
oil & no 
oil 
1-g,
4 a day
-Any Allergic
disease(s)
-Asthma
Linnamaa 
et al., 
2010 (30) 
Reference 
31 
Finland 
2004-08 
Prenatally in 
mothers & 
postnatally in 
mothers & 
infants (2-yrs 
after birth) 
2yrs. No 8-16wks to
2yrs.
postnatal
30-32 322: 151 
vs. 162 
177 
(85 vs. 92) 
Blackcu
rrant 
seed oil 
Olive oil 3 g/day, 
6 
capsules
, oil 
drops in 
infants 
-Eczema
-SPT (egg)
-SCORAD
-Any IgE (mean)
Furuhjelm 
et al., 
2011 (32) 
Reference 
33 
Sweden 
2003-05 
Pre & 
postnatally in 
mothers (3.5 
months after 
birth) 
2yrs Yes 25wks to 
3.5months 
postnatal 
7 to 7.5 145: 70 
vs. 75 
116 
(53 vs. 63) 
ω-3
group 
Mainly 
the 
omega-6 
PUFA 
LA 
500-mg,
nine a
day
-Eczema
-Asthma
-SPT (any+) (egg)
(milk) (food) (wheat)
-Specific IgE
-Food Allergy
-Allergic
Rhinoconjunctivitis
-SCORAD
-IgE (any+) (egg)
(milk) (wheat) (food)
Noakes et References UK. Prenatally in 6mont Yes 20wks to 4.5-5 123: 62 86 (48 vs. Salmon Standar 2 -Wheeze
29 
al., 2012 
(34) 
35-37 No 
reported 
mothers hs delivery vs. 61 38) portions d diet portions 
per 
week 
-Eczema
-SPT (any+) (egg)
(cows milk) (CAT)
(Cod) (grass) (Dog)
-Sensitisation
-Chest infection
-Pneumonia/
bronchiolitis
-SCORAD
-SPT (Derp-1)
-Any IgE
-Itchy skin
-Dry skin
Best et al., 
2016 (38) 
References 
39-42 
Australia 
2006-08 
Prenatally in 
mothers 
6yrs Yes 21wks to 
delivery 
4-5 700: 363 
vs. 337 
603 (313 
vs. 290) 
Included 
in the ITT 
analysis: 
367 vs. 
336 
ω-3 LC-
PUFA 
Vegetab
le oil 
500 mg, 
3 per 
day 
-Allergic disease(s)
with sensitisation
-Eczema with
sensitisation
-Wheeze with
sensitisation
-Rhinitis with
sensitisation
-Rhino-conjunctivitis
with sensitisation
-Sensitisation (any)
-Sensitisation (any+)
(hen’s egg) (peanut)
(cashew) (ryegrass)
(olive tree pollen) (D.
pteronyssinus)
(D.farinae) (Cat hair)
(Alternaria tenius)
(dog hair)
Escamilla-
Nuñez et 
al., 2014 
(43) 
References 
44-46 
Mexico 
2005-07 
Prenatally in 
mothers 
1.5yrs. No 18-22wks 
until 
delivery 
4.5-5.5 1094: 547 
vs. 547 
869 (429 
vs. 440) 
Docosah
exaenoi
c acid 
(DHA) 
A 
mixture 
of corn 
and soy 
oil 
400 mg, 
twice 
per day 
-Wheezing
-Cough
-Breathing Difficulty
-Phlegm & Nasal
-Discharge
-Fever
Hansen References Denmark Prenatally in 24yrs No 30wks to 2-2.5 533: 266 396 (262 Fish oil  Olive 1-g, -Asthma, discharge
30 
2017 (47) 28-29 1989-90 mothers delivery vs. 131 vs. 
136 
vs. 134) oil 4 a day -Asthma medication
-Allergic rhinitis
-sIgE
Bisgaard 
2017 (48) 
Reference 
49 
Denmark
Copenhag
en & 
Zealand 
2008-
2010 
Prenatally and 
postnatally in 
mothers (1-
week after 
birth) 
5yrs. No at week 24 
of 
pregnancy 
to one week 
after 
delivery 
15-
17weeks 
738: not 
specified 
per group 
695 (346 
vs. 349) 
ω-3
LC-
PUFA 
(55% 
EPA 
and 
37% 
DHA) 
in 
triacylgl
ycerol 
form 
Olive oil 2.4 g 
per day 
-Asthma/persistent
wheeze (3-5yrs, birth
to 5yrs),
-Eczema
-Sensitisation (SPT,
sIgE) at 6 or
18months
-Risk of lower
respiratory infection
-Risk of asthma
exacerbations
Berman 
2016 (50) 
References 
51-53 
US, 
South-
eastern 
Michigan 
2008-
2011 
Prenatally in 
mothers 
3yrs No Between 12-
20 gestation 
wks. 
20-28 
wks. 
118: 39 
vs. 38 vs. 
41 
84 (31 vs. 
26 vs. 27) 
EPA-
rich fish 
oil and 
DHA-
rich fish 
oil 
Soy oil 1060mg 
EPA + 
274mg 
DHA 
and 
900mg 
DHA 
plus 180 
mg EPA 
-Eczema
-Food allergies
Asthma/wheezing
*
Published data and conference presentations, no unique data were extracted from conference abstracts 
**
Indicates the number at randomisation, where recruitment has occurred prenatally
31 
Table 2. Definition of outcomes included in the meta-analyses and their diagnostic criteria in individual studies 
Any allergies Diagnosis 
Berman 2016, 3 years follow-up (PPA)
*
Asthma/persistent wheezing (at 3 years) 
Eczema/Skin (at 3 years) 
Food allergies (at 3 years) 
Maternal report in phone interviews, using questions validated from the 2011 NHIS: 
-Chronic long-lasting inflammation of the airways
-Redness, itching, outbreak of lesions
-Abnormal response to food resulting in itching or swelling in mouth, vomiting, diarrhea, abdominal pain
Best 2016, 6 years follow-up (ITT)
**
Allergic diseases symptoms with sensitisation 
Wheeze with sensitisation 
Eczema with sensitisation 
Rhinitis with sensitisation 
Sensitisation (any) 
Hens’ egg sensitisation 
Peanut sensitisation 
Allergic symptoms were recorded using ISAAC questionnaire by nurses at clinic. Sensitisation was 
assessed to at least one of the aeroallergens tested 
-Eczema, wheeze, rhinitis, rhino-conjunctivitis with a positive SPT to ≥1 allergen extracts (sensitisation)
-History of wheezing and/or whistling in the chest within the past 12 months with sensitisation
-Chronic, itchy rash distributed to the facial, flexural or extensor surface of the skin
-History of sneezing or a runny or blocked nose (in the absence of cold or flu) in the past 12 months
-Positive SPT with a wheal size ≥3mm to foods (hen’s egg, peanut, cashew), airborne allergens (ryegrass
pollen, olive tree pollen, alternaria tenius, cat, dog and 2 species of house dust mite
-Positive SPT with a wheal size ≥3mm to hen’s egg
-Positive SPT with a wheal size ≥3mm to peanut
Bisgaard 2016, 3, 5, 0-5 years follow-up 
(ITT) 
Persistent wheeze/asthma (0-5 years) 
Eczema (0-5 years) 
Sensitisation (6 and 18 months of age), SPT 
Sensitisation (6 and 18 months of age), sIgE 
Clinical visits by pediatricians, additional visits for acute care (lung symptoms, any allergy, skin) 
-Diary recordings of five episodes of troublesome lung symptoms, within the preceding 6months,
each lasting for at least 3 consecutive days, symptoms typical of asthma, the rescue use of inhaled
beta
2
-agonist, response to a 3months course of inhaled glucocorticoids following by relapse after
the end of treatment. The diagnosis termed as persistent wheeze by child 3yrs old and asthma
afterwards.
-Based on the criteria defined by Hanifin and Rajka
-A wheal >2mm in response to any SPT to milk, egg, dog or cat allergens
-Specific IgE level of ≥0.35 ku/lit to milk, egg, dog or cat allergens
Dunstan 2003, 1 year follow-up (PPA) 
Recurrent wheeze 
Atopic eczema 
Food allergy 
Clinical evaluations by pediatricians, taking a detailed history and examination: 
-More than 2 episodes of wheezing, at least 1 confirmed by a pediatrician or general practitioner
-Typical skin lesions or physician-diagnosed eczema responsive to topical steroids
-Undefined
32 
Sensitisation 
Sensitisation to egg 
Sensitisation to peanut 
-Using a standardised technique (≥2mm) to allergens as egg, milk, peanut, house dust mite, cat
-Positive SPT with a wheal size ≥2mm to egg
-Positive SPT with a wheal size ≥2mm to peanut
Escamila-Nunez 2014, 1.5 years follow-up 
(PPA) 
Wheezing (maternal atopy and non-atopy) 
Regular follow-ups using a clinical questionnaire, including ISAAC: 
-Symptomatic episode of wheeze as a sign lasting ≥3 days and at least one respiratory symptom
Furuhjelm 2011, 2 years follow-up (PPA) 
Any allergic disease 
Any asthma (cum. incidence 0–24months)  
Any eczema (cum. incidence 0-24 months) 
Any food reactions 
Sensitisation  
Sensitisation to egg 
Examination by pediatrician at 24mon and validated allergy questionnaires completed by families 
-Symptoms of eczema, food reaction, asthma or rhinoconjunctivitis
-Doctor diagnosed wheezing at least three times during the first 2 years of life
-Reoccurring and itching eczematous, lichenified or nummular dermatitis (Seymour criteria 1987)
-Gastrointestinal symptoms, hives, aggravated eczema/wheezing following the ingestion of a
certain food with recovery after food elimination, reoccurrence of symptoms after re-ingestion
-Wheal diameter ≥3 mm to milk, egg, wheat and cat, timothy and birch
-Wheal diameter ≥3 mm to egg
Hansen 2016, 24 years follow-up (ITT) 
Asthma medication  
Allergic rhinitis 
Sensitisation, measured by sIgE (at 18-19yrs 
follow-up, in 243(46%) subjects) 
Information collected from the national prescription register 
-Using a modified validated definition: filled ≥2 prescription for B2-agonist or steroids, ≥1
prescriptions for leukotriene receptor antagonist
-Filled ≥2 prescriptions including: eye drops, nasal decongestants, oral antihistamines
-Positive test result of ≥0.35 ku/l to at least 1 of the 12 allergens
Linnamaa 2011, 1 year follow-up (PPA) 
Atopic eczema 
Clinical evaluation of skin by dermatologist at each visit 
-Chronic or relapsing itchy dermatitis with a characteristic morphology and distribution, based on
the Hanifin criteria
Olsen 2008, 16 years follow-up (PPA) 
Any allergies 
Information extracted from National Patient Registry, a mandatory national hospital discharge 
-Allergic asthma, atopic dermatitis or allergic rhinitis
*
Per-Protocol Analysis
**
Intention-to-treat analysis 
This article is protected by copyright. All rights reserved. 
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Figure 2. Risk of bias assessment figure in the included trials 
Short Title Random Sequence 
Generation 
Allocation 
Concealment 
Double 
Blinding 
Blinding of Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective Outcome 
Reporting 
Other Sources 
of Bias 
Berman 2016 - ? ? ? - + + 
Best 2016 + + - + + + + 
Bisgaard 2016 ? ? + ? + + ? 
Dunstan 2003 ? + + + - + + 
Escamilla-Nuñez 2014 + + + + + + + 
Furuhjelm 2011 ? ? + + - + + 
Hansen 2017 ? + + + + + + 
Linnamaa 2010 + ? + + - + + 
Noakes 2012 + ? - + - + + 
Olsen 2008 ? + - + + + + 
Random Sequence Generation 40% 50% 10% 
Allocation Concealment 50% 50% 
Double Blinding 60% 10% 30% 
Blinding of Outcome 
Assessment 
 
80% 20% 
Incomplete Outcome Data 50% 50% 
Selective Outcome Reporting 100% 
Other Sources of Bias 90% 10% 
Low risk of bias: Unclear risk of bias: High risk of bias: 
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Figure 3. Forest plot for prenatal intake of fatty acid vs. placebo for prevention 
of asthma/wheeze in offspring 
Heterogeneity: Q = 10.5; df = 6; p = 0.104; I-squared = 43.1%; tau-squared = 0.0292 
Random effects model: 0.872 (0.709, 1.07) 
Outcome: Asthma/Wheeze Fatty acid n/N Placebo n/N Study sample 
Berman 2016 13/57 7/27 Unselected 
Best 2016 60/367 45/336 Atopic 
Bisgaard 2016 60/346 87/349 Unselected 
Dunstan 2003 10/40 12/43 Atopic 
Escamila-Nunez 2014 252/429 262/440 Unselected 
Furuhjelm 2011 7/54 8/65 Atopic 
Hansen 2016 31/262 28/136 Unselected 
Total children: 2,951 1,555 1,396 
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Figure 4. Forest plot for prenatal intake of fatty acid vs. placebo for prevention 
of eczema in offspring 
Heterogeneity: Q = 11.2; df = 5; p = 0.0467; I-squared = 55.5%; tau-squared = 0.0599 
Random effects model: 1.01 (0.768, 1.34)  
Outcome: Eczema Fatty acid n/N Placebo n/N Study sample 
Berman 2016 23/57 3/27 Unselected 
Best 2016 36/367 36/336 Atopic 
Bisgaard 2016 114/346 98/349 Unselected 
Dunstan 2003 18/40 13/43 Atopic 
Furuhjelm 2011 11/54 21/65 Atopic 
Linnamaa 2010 33/85 45/92 Unselected 
Total children: 1,861 949 912 
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Figure 5: Forest plot for prenatal intake of fatty acid vs. placebo for prevention 
of sensitisation to egg, measured by SPT in offspring 
Heterogeneity: Q = 1.84; df = 2; p = 0.399; I-squared = 0%; tau-squared = 0 
Random effect model: 0.542 (0.323, 0.908) 
Outcome: Sensitisation 
to egg (SPT) 
Fatty acid n/N Placebo n/N Study sample 
Best 2016 6/248 5/232 Atopic 
Dunstan 2003 9/35 14/37 Atopic 
Furuhjelm 2011 7/52 18/61 Atopic 
Total children: 665 335 330 
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Figure 6: Forest plot for prenatal intake of fatty acid vs. placebo for prevention 
of sensitisation to peanut, measured by SPT in offspring 
Heterogeneity: Q = 0.0658; df = 1; p = 0.798; I-squared = 0%; tau-squared = 0 
Random effect model: 0.621 (0.4, 0.964) 
Outcome: Sensitisation 
to peanut (SPT) 
Fatty acid n/N Placebo n/N Study sample 
Best 2016 27/367 39/336 Atopic 
Dunstan 2003 3/35 6/37 Atopic 
Total children: 775 402 373 
